Definitive radiotherapy for squamous cell carcinoma of the oral cavity

• Verfasst von: Lang, Kristin [VerfasserIn]
• Verfasst von: Baur, Melissa [VerfasserIn]
• Verfasst von: Held, Thomas [VerfasserIn]
• Verfasst von: El-Shafie, Rami [VerfasserIn]
• Verfasst von: Moratin, Julius [VerfasserIn]
• Verfasst von: Freudlsperger, Christian [VerfasserIn]
• Verfasst von: Plath, Karim [VerfasserIn]
• Verfasst von: Bougatf, Nina [VerfasserIn]
• Verfasst von: Hoffmann, Jürgen [VerfasserIn]
• Verfasst von: Plinkert, Peter K. [VerfasserIn]
• Verfasst von: Debus, Jürgen [VerfasserIn]
• Verfasst von: Adeberg, Sebastian [VerfasserIn]
• Titel: Definitive radiotherapy for squamous cell carcinoma of the oral cavity
• Titelzusatz: a single-institution experience
• Verf.angabe: Kristin Lang, Melissa Baur, Thomas Held, Rami El Shafie, Julius Moratin, Christian Freudlsperger, Karim Zaoui, Nina Bougatf, Jürgen Hoffmann, Peter K. Plinkert, Jürgen Debus, Sebastian Adeberg
• E-Jahr: 2021
• Jahr: 19 Nov 2021
• Umfang: 7 S.
• Fussnoten: Gesehen am 20.12.2021
• Titel Quelle: Enthalten in: Radiology and oncology
• Ort Quelle: Warsaw : Sciendo, 2001
• Jahr Quelle: 2021
• Band/Heft Quelle: 55(2021), 4, Seite 467-473
• ISSN Quelle: 1581-3207
• DOI: doi:10.2478/raon-2021-0041
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1782587551

Abstract

Background - Surgery is standard of care for oral cavity cancer (OCC). We provide a single-institution experience using definitive radiotherapy (RT) with or without concurrent systemic therapy for primary unresectable OCC. - - Patients and methods - We retrospectively examined 49 patients with non-metastatic primary unresectable OCC treated with definitive RT between 2000 and 2019. The majority of patients (63.3%) were treated with definitive chemoradiotherapy while 26.5% were given single-agent cetuximab weekly simultaneous to definitive RT. Five patients were treated with definitive RT alone because of limited disease and no nodal involvement. - - Results - Median follow-up was 73 months (range, 6-236 months), median progression free survival (PFS) was 42 months (range, 2-157 months), median local disease-free survival (LDFS) was 44 months (range, 2-157 months) and median overall survival (OS) from the time of RT initiation was 52 months (range, 5-236 months). There were 65.3% locoregional failures, 84.4% local and 15.6% distant metastasis. The majority of patients with local failure presented with American Joint Committee on Cancer (AJCC) Stage III-IV disease (59.2%). The 5-year Kaplan-Meier estimates for OS (III-IV vs. I-II) was 22.8% vs. 54.2 % (p = 0.03, HR 2.090, 1.1-4.2). Patients who were treated with systemic therapy had a significant better 5-year overall survival compared to those with RT